Shares of Twist Bioscience (TWST) skyrocketed 19.27% in the pre-market session on Monday, following the company's impressive fiscal fourth quarter 2024 results that surpassed analyst estimates. The synthetic biology company's strong performance was fueled by robust demand for its synthetic DNA products and services across various industries.

For the fourth quarter, Twist Bioscience reported revenue of $84.7 million, a 26.5% increase from the prior year and topping consensus estimates of $82.2 million. The company's net loss narrowed to $0.59 per share, significantly better than the expected loss of $0.71 per share.

Additionally, Twist Bioscience provided an optimistic outlook for fiscal 2025, forecasting full-year revenue between $367 million and $377 million, exceeding analysts' projections of $371.4 million. The company's proprietary DNA synthesis platform continues to gain momentum, positioning Twist Bioscience as a leader in the rapidly growing synthetic biology market.